在"自然"杂志上发表的两项主要试验中, 中国的马兹杜提德药物显示出强烈的糖尿病和减肥效果. China's mazdutide drug shows strong diabetes and weight loss results in two major trials published in Nature.

由中国开发的双双双GLP-1/GCG受体激动剂Mazdutide(Mazdutide)的两期第3期试验在《自然》上连续发表,标志着该期刊首次连续两次进行第3期代谢疾病研究。 Two Phase 3 trials of mazdutide, a China-developed dual GLP-1/GCG receptor agonist, have been published back-to-back in Nature, marking the first time the journal featured two consecutive Phase 3 metabolic disease studies. “DREAMS-1”和“DREAMS-2”试验显示,马兹杜迪德有效地改善了对血糖的控制,并促使患有2型糖尿病的中国成年人减肥,无论是作为单疗法还是口服药物。 The DREAMS-1 and DREAMS-2 trials showed mazdutide effectively improved blood sugar control and promoted weight loss in Chinese adults with type 2 diabetes, both as monotherapy and with oral medications. 该药以前在《新英格兰医学杂志》上发表的一次减重试验中研究过,是中国首次在两家顶级杂志上推出的先进疗法。 The drug, previously studied in a weight-loss trial published in The New England Journal of Medicine, is the first China-developed therapy to appear in both top-tier journals. 调查结果突显了中国在全球药物创新中不断上升的作用,并可能影响今后的糖尿病治疗准则。 The findings highlight China’s rising role in global drug innovation and may influence future diabetes treatment guidelines.